Urology
Volume 64, Issue 2 , Pages 317-322 , August 2004

Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening

  • Steven E Oliver

      Affiliations

    • Department of Health Sciences, University of York and Hull York Medical School, York, United Kingdom
    • Corresponding Author InformationReprint requests: Steven E. Oliver, Ph.D., M.R.C.P., M.F.P.H.M., Department of Health Sciences, University of York and Hull York Medical School, Seebohm Rowntree Building, Heslington, York YO10 5DD, United Kingdom
    • ,
  • Jeff Holly

      Affiliations

    • Division of Surgery, University of Bristol, Bristol Royal Infirmary, Bristol, United Kingdom
    • ,
  • Tim J Peters

      Affiliations

    • Division of Primary Health Care, University of Bristol, Bristol, United Kingdom
    • ,
  • Jenny Donovan

      Affiliations

    • Department of Social Medicine, University of Bristol, Bristol, United Kingdom
    • ,
  • Raj Persad

      Affiliations

    • Division of Surgery, University of Bristol, Bristol Royal Infirmary, Bristol, United Kingdom
    • ,
  • David Gillatt

      Affiliations

    • Bristol Urological Institute, Southmead Hospital, Bristol, United Kingdom
    • ,
  • Anya Pearce

      Affiliations

    • Division of Surgery, University of Bristol, Bristol Royal Infirmary, Bristol, United Kingdom
    • ,
  • Freddie C Hamdy

      Affiliations

    • Academic Urology Unit, Division of Clinical Sciences, University of Sheffield, Sheffield, United Kingdom
    • ,
  • David E Neal

      Affiliations

    • Oncology Centre, Addenbrooke's Hospital, Cambridge, United Kingdom
    • ,
  • David Gunnell

      Affiliations

    • Department of Social Medicine, University of Bristol, Bristol, United Kingdom

Received 17 June 2003 ,Accepted 9 March 2004.

References 

  1. Selley S, Donovan J, Faulkner A, et al.  Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess. 1997;1:1–96
  2. Catalona WJ, Partin AW, Slawin KM, et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease (a prospective multicenter clinical trial). JAMA. 1998;279:1542–1547
  3. Chan JM, Stampfer MJ, Giovannucci E, et al.  Plasma insulin-like growth factor-I and prostate cancer risk (a prospective study). Science. 1998;279:563–566
  4. Wolk A, Mantzoros CS, Andersson SO, et al.  Insulin-like growth factor 1 and prostate cancer risk (a population-based, case-control study). J Natl Cancer Inst. 1998;90:911–915
  5. Chan JM, Stampfer MJ, Ma J, et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002;94:1099–1106
  6. Chokkalingam AP, Pollak M, Fillmore C-M, et al.  Insulin-like growth factors and prostate cancer (a population-based case-control study in China). Cancer Epidemiol Biomarkers Prev. 2001;10:421–427
  7. Stattin P, Bylund A, Rinaldi S, et al.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk (a prospective study). J Natl Cancer Inst. 2000;92:1910–1917
  8. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000;183:1–9
  9. Wolk A, Andersson S-O, Mantzoros CS, et al.  Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?. Lancet. 2000;356:1902–1903
  10. Djavan B, Bursa B, Seitz C, et al.  Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology. 1999;54:603–606
  11. Ismail AH, Pollak M, Behlouli H, et al.  Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. J Urol. 2002;168:2426–2430
  12. Donovan J, Hamdy F, Neal D, et al.  Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7:1–88
  13. Oliver SE, Gunnell D, Donovan J, et al.  Screen-detected prostate cancer and the insulin-like growth factor axis (results of a population-based case-control study). Int J Cancer. 2004;108:887–892
  14. Cheetham TD, Holly JM, Baxter RC, et al.  The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus. J Endocrinol. 1998;157:81–87
  15. Dorfman DD, Alf E. Maximum likelihood estimation of signal detection theory and determination of confidence intervals-rating method data. J Math Psychol. 1969;6:487–496
  16. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves (a nonparametric approach). Biometrics. 1988;44:837–845
  17. StataCorp . Stata Statistical Software: Release 7.0. College Station, Texas: Stata Corporation; 2001;
  18. Finne P, Auvinen A, Koistinen H, et al.  Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab. 2000;85:2744–2747
  19. Khosravi J, Diamandi A, Mistry J, et al.  Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab. 2001;86:694–699
  20. Cutting CWM, Hunt C, Nisbet JA, et al.  Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int. 1999;83:996–999
  21. Chokkalingam AP, Gao YT, Deng J, et al.  Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate. 2002;52:98–105

☆ This research was funded by NHS South and West R&D; and the ProtecT treatment trial was funded by the NHS Health Technology Assessment Programme.

PII: S0090-4295(04)00335-8

doi: 10.1016/j.urology.2004.03.018

Urology
Volume 64, Issue 2 , Pages 317-322 , August 2004

Article Tools

* Image Usage & Resolution